Autologous bone marrow transplantation is an alternative therapeutic option for @entity3052 @entity1 lacking a compatible donor. However, bone marrow from these @entity1 may contain residual leukemic cells that should be ideally eliminated prior to the infusion of the graft. With the aim of developing more efficient protocols of graft purging, adenoviral-mediated gene transfer protocols have been conducted. We studied whether suicide adenoviral vectors expressing the cytosine deaminase gene (AdCD) could be used for selectively killing leukemic WEHI-3B cells. The AdCD transduction followed by the 5-fluorocytosine exposure abrogated the growth of WEHI-3B cells in vitro, with a minimal effect on normal hematopietic progenitors. To test the efficacy of the purging protocol in vivo, bone marrow cells were mixed with syngenic WEHI-3B cells and this chimeric cell population was transduced with AdCD vectors. Infected cells were injected into myeloablated Balb-c @entity19 , which then received a 5-fluorocytosine treatment for 4 days. All @entity19 transplanted with unpurged bone marrow developed @entity1778 and died. However, 90% of recipients receiving the purging treatment were healthy up to 9 months post-transplantation and had a perfectly re-established hematopoietic system, without any signal of leukemic cell presence. In conclusion, suicide adenoviral vectors are proposed as a tool for the purging of @entity2800 cells contaminating autologous bone marrow grafts.

Purging of XXXX -contaminated bone marrow grafts using suicide adenoviral vectors: an in vivo @entity19 experimental model.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['Adenoviral-susceptible myeloid leukemia'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['leukemia']
@entity1778 :: (MESH:D007938,Disease) :: ['leukemia']
